Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine (Q43105406)

14 November 2017

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine (English)

1 reference

14 November 2017

myelodysplastic syndrome

1 reference

8

Hagop Kantarjian

1 reference

14 November 2017

5

Alessandra Ferrajoli

1 reference

14 November 2017

4

Stefan Faderl

1 reference

14 November 2017

3

Farhad Ravandi

1 reference

14 November 2017

1

Gautam Borthakur

1 reference

14 November 2017

7

Jean-Pierre Issa

1 reference

14 November 2017

Samih El Ahdab

2

1 reference

PMC publication ID

3702160

14 November 2017

Beth Newman

series ordinal

6

1 reference

14 November 2017

1 April 2008

1 reference

14 November 2017

1 reference

14 November 2017

49

1 reference

14 November 2017

4

1 reference

14 November 2017

690-695

1 reference

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

14 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

International scoring system for evaluating prognosis in myelodysplastic syndromes

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

High sensitivity mapping of methylated cytosines

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702160

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

15 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F10428190701882146

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18398735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18398735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18398735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/10428190701882146

1 reference

14 November 2017

1 reference

PMC publication ID

3702160

14 November 2017

PubMed publication ID

18398735

1 reference

PMC publication ID

3702160